{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:49:16Z","timestamp":1792601356581,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-58186-7","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T09:29:05Z","timestamp":1742635745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-4465","authenticated-orcid":false,"given":"Kentaro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-0077","authenticated-orcid":false,"given":"Jun","family":"Sugisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-8301","authenticated-orcid":false,"given":"Takayo","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tsuchiya-Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-9776","authenticated-orcid":false,"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"58186_CR1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger, S. et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J. Clin. Oncol. 36, 1675\u20131684 (2018).","journal-title":"J. Clin. Oncol."},{"key":"58186_CR2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10147-019-01588-7","volume":"25","author":"K Chamoto","year":"2020","unstructured":"Chamoto, K., Hatae, R. & Honjo, T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int. J. Clin. Oncol. 25, 790\u2013800 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"58186_CR3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"New Engl. J. Med."},{"key":"58186_CR4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. New Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"New Engl. J. Med."},{"key":"58186_CR5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. New Engl. J. Med. 379, 2040\u20132051 (2018).","journal-title":"New Engl. J. Med."},{"key":"58186_CR6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"58186_CR7","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"New Engl. J. Med."},{"key":"58186_CR8","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. New Engl. J. Med. 389, 1672\u20131684 (2023).","journal-title":"New Engl. J. Med."},{"key":"58186_CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 198\u2013211 (2021).","journal-title":"Lancet Oncol."},{"key":"58186_CR10","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson, M. L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J. Clin. Oncol. 41, 1213\u20131227 (2023).","journal-title":"J. Clin. Oncol."},{"key":"58186_CR11","first-page":"192","volume":"42","author":"DSW Tan","year":"2024","unstructured":"Tan, D. S. W. et al. Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial. J. Clin. Oncol. 42, 192\u2013204 (2024).","journal-title":"J. Clin. Oncol."},{"key":"58186_CR12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel, S. A. et al. Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy. Clin. Cancer Res. 29, 30\u201339 (2023).","journal-title":"Clin. Cancer Res."},{"key":"58186_CR13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096\u20131103 (1996).","journal-title":"Nat. Med."},{"key":"58186_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4049\/jimmunol.174.1.215","volume":"174","author":"MM Dikov","year":"2005","unstructured":"Dikov, M. M. et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174, 215\u2013222 (2005).","journal-title":"J. Immunol."},{"key":"58186_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139\u2013148 (2015).","journal-title":"J. Exp. Med."},{"key":"58186_CR16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","volume":"128","author":"KH Parker","year":"2015","unstructured":"Parker, K. H., Beury, D. W. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128, 95\u2013139 (2015).","journal-title":"Adv. Cancer Res."},{"key":"58186_CR17","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. New Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"New Engl. J. Med."},{"key":"58186_CR18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"New Engl. J. Med."},{"key":"58186_CR19","doi-asserted-by":"crossref","unstructured":"Shiraishi, Y. et al. Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 10, 315\u2013324 (2023).","DOI":"10.1001\/jamaoncol.2023.5258"},{"key":"58186_CR20","doi-asserted-by":"crossref","first-page":"e0284131","DOI":"10.1371\/journal.pone.0284131","volume":"18","author":"M Yamakuchi","year":"2023","unstructured":"Yamakuchi, M. et al. VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals. PLoS ONE 18, e0284131 (2023).","journal-title":"PLoS ONE"},{"key":"58186_CR21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/1078-0432.CCR-12-2535","volume":"19","author":"PS Hegde","year":"2013","unstructured":"Hegde, P. S. et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin. Cancer Res. 19, 929\u2013937 (2013).","journal-title":"Clin. Cancer Res."},{"key":"58186_CR22","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119\u20132127 (2012).","journal-title":"J. Clin. Oncol."},{"key":"58186_CR23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","volume":"70","author":"D Miles","year":"2017","unstructured":"Miles, D. et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur. J. Cancer 70, 146\u2013155 (2017).","journal-title":"Eur. J. Cancer"},{"key":"58186_CR24","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl. J. Med. 355, 2542\u20132550 (2006).","journal-title":"New Engl. J. Med."},{"key":"58186_CR25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669\u2013676 (2003).","journal-title":"Nat. Med."},{"key":"58186_CR26","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1158\/0008-5472.CAN-12-0762","volume":"72","author":"A Carrer","year":"2012","unstructured":"Carrer, A. et al. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res. 72, 6371\u20136381 (2012).","journal-title":"Cancer Res."},{"key":"58186_CR27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/cgt.2016.12","volume":"23","author":"M Kazemi","year":"2016","unstructured":"Kazemi, M. et al. VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans. Cancer Gene Ther. 23, 125\u2013132 (2016).","journal-title":"Cancer Gene Ther."},{"key":"58186_CR28","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.3892\/ol.2016.5287","volume":"12","author":"MS Hung","year":"2016","unstructured":"Hung, M. S. et al. Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncol. Lett. 12, 4598\u20134604 (2016).","journal-title":"Oncol. Lett."},{"key":"58186_CR29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"58186_CR30","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-14-3282","volume":"75","author":"M Saito","year":"2015","unstructured":"Saito, M. et al. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Cancer Res. 75, 2264\u20132271 (2015).","journal-title":"Cancer Res."},{"key":"58186_CR31","doi-asserted-by":"crossref","unstructured":"Sugiyama, E. et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci. Immunol. 5, eaav3937 (2020).","DOI":"10.1126\/sciimmunol.aav3937"},{"key":"58186_CR32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26, 688\u2013692 (2020).","journal-title":"Nat. Med."},{"key":"58186_CR33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"58186_CR34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","volume":"7","author":"M Pinter","year":"2021","unstructured":"Pinter, M., Jain, R. K. & Duda, D. G. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 7, 113\u2013123 (2021).","journal-title":"JAMA Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58186-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T09:30:19Z","timestamp":1742635819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58186-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58186"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58186-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.T. has received personal fees from Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck, Takeda Pharmaceutical, Pfizer, MSD, Novartis and Bristol Myers Squibb outside the submitted work. Y Shiraishi has received personal fees from Ono Pharmaceutical, Taiho Pharmaceutical, AstraZeneca, Ono Pharmaceutical and Bristol Myers Squibb outside the submitted work. H.D. has received personal fees from AstraZeneca outside the submitted work. K.A. has received personal fees from Chugai Pharmaceutical, Takeda Pharmaceutical, MSD, AstraZeneca, and Bristol Myers Squibb outside the submitted work. K.N. has received grants from Ono Pharmaceutical, Taiho Pharmaceutical, MSD, AbbVie, Daiichi Sankyo, Amgen, Eisai, Sanofi, Janssen Pharmaceutical, Novartis, Pfizer, Eli Lilly, Merck, Takeda Pharmaceutical, Chugai Pharmaceutical and AstraZeneca; and personal fees from AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Novartis, Pfizer, Merck, Janssen Pharmaceutical, Bristol Myers Squibb and Nihon Kayaku outside the submitted work. M M. has received personal fees from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, Eli Lilly, Kyowa Hakko Kirin, MSD, Nihon Kayaku, Pfizer, Taiho Pharmaceutical, Takeda Pharmaceutical and AbbVie outside the submitted work. H.S. has received grants from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical and Bristol Myers Squibb; and personal fees from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical and Bristol Myers Squibb, Boehringer Ingelheim and Pfizer outside the submitted work. A.H. has received grants from MSD, Eli Lilly, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim and AstraZeneca; and personal fees from MSD, Eli Lilly, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer and AstraZeneca outside the submitted work. T.S. has received personal fees from MSD, Eli Lilly, Chugai Pharmaceutical, Merck, Ono Pharmaceutical and AstraZeneca outside the submitted work. T.K. has received grants from Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Taiho Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, MSD, Kyowa Hakko Kirin, Merck, Daiichi-Sankyo, Amgen, Abbvie, Sanofi, Labcorp development Japan, IQVIA Services Japan, Gilead Sciences, Pfizer and Bayer; consulting fees from Chugai Pharmaceutical, AstraZeneca, Ono Pharmaceutical, Pfizer, Daiichi-Sankyo, Bayer and Abbvie; and personal fees from Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Taiho Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, MSD, Pfizer, Kyowa Hakko Kirin, Boehringer Ingelheim, Merck, Nihon Kayaku, Novartis, Daiichi-Sankyo, Takeda Pharmaceutical, Bayer, Sawai, Amgen and Eisai outside the submitted work. H.A. has received grants from Amgen, Boehringer Ingelheim; personal fees from Amgen, Chugai Pharmaceutical, AstraZeneca, Eli Lilly, Taiho Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, MSD, Pfizer, Boehringer Ingelheim, Merck, Nihon Kayaku, Novartis, Daiichi-Sankyo, Takeda Pharmaceutical; fees for membership of an advisory board for Amgen, Janssen Pharmaceutical, Sandoz and MSD outside the submitted work. H.M. has personal fees from AstraZeneca, Boehringer Ingelheim, Ono Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical and MSD outside the submitted work. M.T. has received grants from AstraZeneca, Chugai Pharmaceutical and Eli Lilly; personal fees from Eli Lilly, Ono Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, AstraZeneca, MSD, Novartis pharmaceuticals, Takeda Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Daiichi Sankyo, Pfizer and Janssen Pharmaceutical outside the submitted work. K.W. has received grants from Chugai Pharmaceutical, AstraZeneca, Novartis, Abbvie, Amgen, MSD and Daiichi Sankyo; personal fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Ono Pharmaceutical, MSD, AstraZeneca, Daiichi Sankyo, Janssen Pharmaceutical and Takeda Pharmaceutical outside the submitted work. Y Sato has received personal fees from AstraZeneca, MSD, Novartis, Chugai Pharmaceutical, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, Nihon Kayaku, Bristol Myers Squibb, Eli Lilly, Takeda, Kyowa Hakko Kirin and Daiichi Sankyo outside the submitted work. Y. T. K. has received personal fees from Bristol Myers Squibb, Taiho Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Kyowa Hakko Kirin, MSD, Ono Pharmaceutical and Takeda Pharmaceutical outside the submitted work. N.Y. has received grants from Boehringer Ingelheim, Taiho Pharmaceutical, Chugai Pharmaceutical, Shionogi, Eli Lilly, Daiichi Sankyo, Tumura, Nihon Kayaku, Asahikasei-pharma, AstraZeneca, Janssen, Sanofi, Amgen, Novartis, Astellas, MSD, Esai, Bristol-Myers Squibb, Abbvie and Tosoh; and personal fees from MSD, AstraZeneca, Amgen, Ono Pharmaceutical, Otsuka, Guardant Health Japan, Tumura, Kyowa Hakko Kirin, Kyorin, GlaxoSmithKline, Sanofi, Daiichi Sankyo, Taiho Pharmaceutical, Takeda, Chugai Pharmaceutical, Eli Lilly, Nippon Kayaku, Boehringer Ingelheim, Novartis, Pfizer, Bristol Myers Squibb, Miyarisan, Merck and Janssen; and fees for membership of a data safety monitoring board or an advisory board from AstraZeneca, Eli Lilly, and Takeda outside the submitted work. K.N. has received grants from AstraZeneca, SD, Ono Pharmaceutical, Boehringer Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, Eli Lilly, Chugai Pharmaceutical, Daiichi Sankyo, Merck, PAREXEL International, PRA HEALTHSCIENCES, EPS Corporation., Kissei Pharmaceutical, EPS International, Taiho Pharmaceutical, PPD-SNBL, SymBio Pharmaceuticals, IQVIA Services JAPAN, SYNEOS HEALTH CLINICAL, Nihon Kayaku, EP-CRSU, Mebix, Janssen, AbbVie, Bayer, Eisai, Mochida Pharmaceutical, Covance Japan, Japan Clinical Research Operations, Takeda, GlaxoSmithKline, Sanofi, Sysmex, Medical Reserch Support, Otsuka Pharmaceutical, SRL, and Amgen; and consulting fees from Eli Lilly, Kyorin Pharmaceutical, Ono Pharmaceutical and Pfizer; and personal fees from Ono Pharmaceutical, Amgen, Nippon Kayaku, AstraZeneca, Chugai Pharmaceutical, Eli Lilly, MSD, Pfizer, Boehringer Ingelheim, Taiho Pharmaceutical, Bayer, CMIC ShiftZero, Life Technologies Japan, Neo Communication, Roche Diagnostics, AbbVie, Merck, Kyowa hakko Kirin, Takeda, 3H Clinical Trial, Care Net, Medical Review, Medical Mobile Communications, YODOSHA, Nikkei Business Publications, Japan Clinical Research Operations, CMIC, Novartis, TAIYO Pharma, Kyorin Pharmaceutical, and Bristol-Myers Squibb; and patents from Daiichi Sankyo outside submitted work. I.O. has received grants from Chugai Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, MSD, Eli Lilly, Astellas, Bristol Myers Squibb, Novartis, Pfizer, and AbbVie; and consulting fee from AstraZeneca, Bristol Myers Squibb, and AbbVie; and personal fees from AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Chugai Pharmaceutical, Ono Pharmaceutical, MSD, Eli Lilly, Bristol-Myers Squibb, Novartis, and Pfizer outside the submitted work. J.S., T Ota and T Ozaki declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2825"}}